company background image
2256 logo

Abbisko Cayman SEHK:2256 Stock Report

Last Price

HK$3.30

Market Cap

HK$2.1b

7D

-4.3%

1Y

20.4%

Updated

29 May, 2024

Data

Company Financials +

Abbisko Cayman Limited Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Abbisko Cayman
Historical stock prices
Current Share PriceHK$3.30
52 Week HighHK$4.69
52 Week LowHK$2.05
Beta1.48
1 Month Change-0.60%
3 Month Change21.77%
1 Year Change20.44%
3 Year Changen/a
5 Year Changen/a
Change since IPO-73.39%

Recent News & Updates

Here's Why We're Not Too Worried About Abbisko Cayman's (HKG:2256) Cash Burn Situation

Apr 27
Here's Why We're Not Too Worried About Abbisko Cayman's (HKG:2256) Cash Burn Situation

Recent updates

Here's Why We're Not Too Worried About Abbisko Cayman's (HKG:2256) Cash Burn Situation

Apr 27
Here's Why We're Not Too Worried About Abbisko Cayman's (HKG:2256) Cash Burn Situation

An Intrinsic Calculation For Abbisko Cayman Limited (HKG:2256) Suggests It's 37% Undervalued

Jan 09
An Intrinsic Calculation For Abbisko Cayman Limited (HKG:2256) Suggests It's 37% Undervalued

Will Abbisko Cayman (HKG:2256) Spend Its Cash Wisely?

Nov 01
Will Abbisko Cayman (HKG:2256) Spend Its Cash Wisely?

We Think Abbisko Cayman (HKG:2256) Can Afford To Drive Business Growth

Jun 08
We Think Abbisko Cayman (HKG:2256) Can Afford To Drive Business Growth

Shareholder Returns

2256HK BiotechsHK Market
7D-4.3%-6.9%-0.7%
1Y20.4%-35.7%4.9%

Return vs Industry: 2256 exceeded the Hong Kong Biotechs industry which returned -35.7% over the past year.

Return vs Market: 2256 exceeded the Hong Kong Market which returned 4.9% over the past year.

Price Volatility

Is 2256's price volatile compared to industry and market?
2256 volatility
2256 Average Weekly Movement6.8%
Biotechs Industry Average Movement9.5%
Market Average Movement7.4%
10% most volatile stocks in HK Market15.6%
10% least volatile stocks in HK Market3.8%

Stable Share Price: 2256's share price has been volatile over the past 3 months.

Volatility Over Time: 2256's weekly volatility (7%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
2016258Yao-Chang Xuwww.abbisko.com

Abbisko Cayman Limited, a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule oncology therapies in Mainland China. The company’s product candidates are primarily small molecules that focus on small molecule precision oncology and small molecule immuno-oncology therapeutic areas. It is also involved in the research and development in areas of biomedical and biotechnology; and provision of technical and technical consultation services.

Abbisko Cayman Limited Fundamentals Summary

How do Abbisko Cayman's earnings and revenue compare to its market cap?
2256 fundamental statistics
Market capHK$2.14b
Earnings (TTM)-HK$465.08m
Revenue (TTM)HK$20.54m

104.1x

P/S Ratio

-4.6x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
2256 income statement (TTM)
RevenueCN¥19.06m
Cost of RevenueCN¥0
Gross ProfitCN¥19.06m
Other ExpensesCN¥450.64m
Earnings-CN¥431.58m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-0.67
Gross Margin100.00%
Net Profit Margin-2,264.34%
Debt/Equity Ratio0%

How did 2256 perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.